Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 2Recurrence 1Non-Small Cell Lung Cancer ALK-positive 1Neurofibromatosis 1 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Hereditary Sensory and Autonomic Neuropathies 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Brain Neoplasms 1Astrocytoma 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

Fulvestrant 4ribociclib 2palbociclib 2Irinotecan 2Gemcitabine 2venetoclax 1tivozanib 1serabelisib 1sapanisertib 1niraparib 1lorlatinib 1liposomal doxorubicin 1inavolisib 1exemestane 1encorafenib 1cemiplimab 1binimetinib 1abemaciclib 1Taxes 1Tamoxifen 1STX-478 1Paclitaxel 1Metformin 1Lomustine 1Letrozole 1Imlunestrant 1Doxorubicin 1Cetuximab 1Carboplatin 1CA-4948 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × lorlatinib × 90 days × Clear all
NCT04800822 2026-06-04

PF-07284892 in Participants With Advanced Solid Tumors

Pfizer

Phase 1 Terminated
53 enrolled
CNSGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡